

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

1.164.569



PATENT SPECIFICATION

NO DRAWINGS

1.164.569

Date of Application (No. 35291/68) and filing Complete Specification: 24 July, 1968.

Application made in Spain (No. 343,957) on 9 Aug., 1967.

Complete Specification Published: 17 Sept., 1969.

Index at acceptance:—C3 U(2C5, 3E, 4A3A, 4A3X, 4B2C, 4E, 4F, 4L); A5 B(23Y, 231, 38Y, 382)

International Classification:—C 08 b 19/02

COMPLETE SPECIFICATION

Improvements in or relating to Antilipaemic Sulphated Polysaccharides

We, RÓCADOR SOCIEDAD ANONIMA, a Spanish Joint-Stock Company, of Clavé 96—102, Esplugas de Llobregat, Province of Barcelona, Spain, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in, and by the following statement:—

The present invention relates to a new antilipaemic sulphated polysaccharide which is active under oral administration, and to a method for the production of the same.

The sulphated polysaccharides (heparinoids) are known to possess the property of increasing the anticoagulant capacity of blood when administered parenterally and to cause the disappearance of the fats found in dispersion in blood serum. This property appears to be characteristic of high linear polymers receiving negative electrical charges during conversion into the sulphate. Among the said sulphated polysaccharides, dextran sulphate is particularly well known.

The antilipaemic activity is based on the stimulus to release a lipoproteinlipase [expressed in terms of clarifying factor (C.F.)] and is a function of the molecular weight of the dextran and of the degree of sulphonation. Molecular weights lower than 1200 result in inactive products, whereas molecular weights higher than 20,000 result in products which are toxic under parenteral administration. The molecular weight is a function of the intrinsic viscosity, which should, therefore, lie between 0.02 and 0.07.

To obtain the appropriate molecular weights, the process usually used consists in the hydrolysis of dextran in an acid medium or in an oxidising, thermic, enzymatic or other suitable medium. The degree of sulphation

should suitably be maintained between 10 and 20% of sulphur, in its potassium salt, i.e. equivalent to from 1 to 3 —SO₃— groups to each monosaccharide group. The known synthesis of sulphated dextran comprises sulphating dextran with chlorosulphonic acid or sulphur trioxide in an organic medium, such as pyridine or picoline (either alone or dissolved in formamide), whilst keeping the reaction temperature at approximately 60°C for a number of hours. After cooling, neutralising and dialysing, the sulphated dextran is precipitated with organic solvents. A variety of salts of the sulphated dextran so produced may be employed: e.g. sodium salts, potassium salts, ammonium salts, as well as alkyl and oxyalkylamine salts, and salts of other organic bases.

These heparinoid sulphated polysaccharides characteristically cause the release of lipoproteinlipase on penetrating into the bloodstream of a living animal. This release of lipoproteinlipase may be observed by the reduction in turbidity occurring on mixing 2cc of citrated plasma extracted 10 minutes after injecting heparin, or two hours after injecting the heparinoid sulphated polysaccharide intravenously, in a dosage of 2 to 4 mg per Kg, with 0.1 to 0.2 cc of a freshly prepared 5% suspension of Ediol (trade name of Schenlabs Pharmaceuticals). The optical densities are determined with a red filter before mixing and after 15 and 30 minutes following preparation of the mixture. The mixture is kept at 37°C in 1 cm test tubes.

The antilipaemic capacity of these heparinoid sulphated polysaccharides, in comparison with that of heparin, is shown in Table I which gives values of optical densities:

TABLE I

Dose	Heparin	Sulphated polysaccharide	
	3.5 mg/Kg	2.5 mg/Kg	3 mg/Kg
Times: 0 minutes	0.540	0.545	0.535
15 minutes	0.450	0.360	0.305
30 minutes	0.370	0.295	0.265

Parenteral administration of the product has the disadvantage of the inconvenience of administering a product whose activity lasts for 6 hours and which should logically be administered at least twice daily.

It was found moreover that oral administration is not very effective as the product is absorbed or altered in the digestive tract. This problem has been partially overcome by simultaneously administering calcium or magnesium complexing agents, or by coating the product to protect it against gastric juices.

Oral absorption can be determined by measuring the increase in the concentration of fatty acids released at the expense of triglycerides, after a greasy meal, taking blood samples at different times before and after imbibing the composition. It is possible to perform this determination according to the method of Dole and Kern (J. Lipid. Research, 2, 51, 1961), expressing the results in micromols of fatty acids per cc of serum. The normal figures are of the order of 0.4 to 0.7 micromols, although there are known sulphated dextrans which, without the addition of complexants or coating, raise the fatty acid content of from 1 to 1.2 micromols per cc, when taken at a dosage of 150 mg.

The novel sulphated polysaccharide of the present invention makes it possible to increase the said fatty acid content to from 2 to 3 micromols per cc. when taken at a dosage of 150 mg.

The present invention consists in a sulphated polysaccharide which is a salt of sulphated hydrodextran having an average sulphur content of from 1 to 3 SO₂ groups per monosaccharide group, and being substantially non-reducing as determined by the Somogyi method. Its intrinsic viscosity at 25°C preferably lies between 0.02 to 0.07.

The general scope of the invention covers all the pharmaceutically acceptable salts. Alkali metal salts having a sulphur content of 10 to 20% of the total weight are of special interest.

The invention further consists in a method of preparing said salt of a sulphated hydrodextran which comprises sulphating a hydrodextran, preferably having an intrinsic vis-

cosity of between 0.02 and 0.07 at 25°C, and possessing a reducing capacity as determined by the Somogyi method lower than 0.5% expressed in glucose, followed by salt formation.

Dextran is a polymer of glucose, with a majority of -1-6-1-6 bonds, such that the last cycle of the chain is a glucose unit possessing a pyranose ring formed by an oxygen bridge in the enolic form of the aldehyde in the 6th carbon position. This ring is of a reducing nature with respect to alkaline cupric solutions (Fehling, Somogyi & others). The reducing power of the dextran employed lies between one tenth and one twentieth of that of glucose.

During the hydrogenation of dextran, the final reducing ring of the chain is converted into a polyol, so that the reducing power of hydrodextran is practically negligible (approximately 0.5% of that of glucose).

During sulphation of dextran, the enolic hydroxide of the 6th carbon atom in the final link of the chain is also sulphated, so that the differences in reducing power compared to hydrodextran are reduced considerably.

Moreover, applying the Somogyi method, it has been found that 50 mg of glucose have the same reducing power as 25 grames or less of sulphated dextran, and as 60 grames of more of sulphated hydrodextran.

Hydrodextran is produced by hydrogenation of a dextran, suitably possessing an intrinsic viscosity of between 0.02 and 0.07 at 25°C (approximately equivalent to a molecular weight of between 1500 and 3500). The hydrogenation may be effected by an electrolytic process using sodium or potassium amalgam in which mercury acts as a cathode, or by using sodium borohydride in aqueous solution from which hydrodextran is recovered after de-ionisation with ion exchanger resins, or else by direct hydrogenation in the presence of catalytic nickel, or by other conventional physico-chemical processes.

Once it has been sulphated by any of the processes applicable to dextran and other polysaccharides, hydrodextran will form salts, the most common being those of potassium

and of sodium. Salts may also be formed with various organic bases, such as diethylamine and monoethylamine, or with pyridoxine or thiamine.

- 5 The differences in activity, as shown by the capacity to release lipasic units, between the potassium salt of sulphated dextran and the potassium salt of sulphated hydrodextran, are apparent from the following Table II. The
10 values in the second and third columns were

determined by the Dole and Kern method and represent the average of lipasic units (micromols of fatty acids per cc of serum) of two groups of 4 persons who had received 150 mg of medication per person and per dose, together with fatty food amounting to 900 Kcal. Blood samples were taken before administration of the medication and 1, 2, 4 and 6 hours after administration.

15

TABLE II

hours	lipasic units				
	0	1	2	4	6
potassium salt of sulphated dextran	0.55	1.10	1.12	0.9	0.68
potassium salt of sulphated hydrodextran	0.43	2.37	2.11	0.85	0.89

Appreciable differences are also observed in anti-coagulant property by evaluation *in vitro* according to the method of Marvin-H. Knizenga (J.Biol.Chem., 139, 612) employing sheep's blood. 1 mg of the potassium salt of sulphated dextran has 12 International Units of anticoagulant activity when its intrinsic viscosity is between 0.04 and 0.07 and its sulphur content is from 14 to 16%, whereas the potassium salt of sulphated hydrodextran possessing the same viscosity and proportion of sulphur, exhibits no more than 6 International Units of activity.

- 25 The invention is now further illustrated with reference to the following Examples.

EXAMPLE 1

225 litres of water were placed into a vessel equipped with a reflux system and a stirring mechanism, and the temperature was raised to boiling point. 15 kilogrammes of dextran, having a molecular weight of 250,000 and 15 litres of 1N H₂SO₄, were then added. Boiling was continued for a number of hours, whilst the relative viscosity at 25°C was checked at regular intervals until it reached the value of 1.3. The solution was then neutralised with 1.5 litres of 10N NaOH. The mixture was cooled and 225 litres of acetone were added. The batch was allowed to stand for 24 hours, and the dextran content was precipitated from the clear decanted part, by means of another batch of 225 litres of acetone. The precipitate obtained was dissolved in 50 litres of water and dialysed for 24 hours. The liquids so obtained were then concentrated down to 200 litres, and the dextran was precipitated by means of 400 litres of isopropyl alcohol.

- 20 The precipitate obtained contained approximately 4 kg of dry dextran, having an intrinsic viscosity at 25°C of 0.05 and a reducing

power equivalent to 7% of glucose, as determined by the Somogyi method.

The dextran was dissolved in water to produce a 20% solution and was then hydrogenated. In order to effect the hydrogenation, 20 litres of this dextran solution were made alkaline by the addition of a 40% (by volume) solution of NaOH and placed in the cationic region of a cell with a mercury cathode possessing a surface area of approximately 4 dm². A 10% solution of sodium sulphate was placed in a porous vessel of capacity 500 cc. The anode was a platinum rod, of length of 15 cms and diameter 2.5 mm. A current of approximately 10 amps was passed through the solution which was cooled. A stirrer maintained constant agitation throughout the solution. Samples were taken periodically to determine the reducing capacity; when this latter reached a value at which 1 cc was equivalent to 1 mg of glucose, the reduction was considered to have been completed. After filtering the solution, its alkalinity was eliminated by means of cationic Lewatite (Registered Trade Mark) S-100 resin (trade name of Bayer A.G.) and the pH thus adjusted to between 6.5 and 7.0. Precipitation was then performed with twice its volume of alcohol, the solution being allowed to stand for two days. The superjacent liquid was decanted, the precipitate collected and dried, and 2.5 kg of hydrodextran were obtained possessing the following characteristics: ash content 6.7%, reducing capacity being of such order that 20 g is equivalent to 50 mg of glucose, refractive index (alpha) of +185°, and intrinsic viscosity 0.04.

The hydrodextran obtained was sulphated by the following method. 8 litres of pyridine were charged into a 20 litre capacity vessel, equipped with a stirring mechanism and a

65

70

75

80

85

90

95

100

The physico-chemical characteristics of the sodium salt of sulphated hydrodextran are:

To demonstrate the effect of phosphatidylcholine on blood lipid levels, a study was conducted on laboring rats. The rats were fed on a high fat diet and a dosage of phosphatidylcholine was evaluated. The results showed that the made on cholesterol, lipoproteins, and triglycerides starting the following day. The results were identical to the control animals which were on the same diet.

EXAMPLE 2

dextran was precipitated with methyl alcohol, giving approximately 3 kg having the following characteristics: reducing power against Somogyi reagent, practically none, refractive index (α) = $+170^\circ$, intrinsic viscosity 0.05.

This hydrodextran was then sulphated. 3 kg of SO_3 were added a little at a time to 8 kg of pyridine cooled to -10°C whilst stirring, and the temperature was maintained below 0°C . 1.6 kg of hydrodextran were added after raising the temperature to between 25 and 30°C . The exothermicity of the mixture raised the temperature which was then maintained at between 65 and 75°C for 8 to 10 hours. The solution was cooled and neutralized by adding 4.9 kg of 70% (by volume) caustic potash. The solution was then allowed to stand, thereby decanting the greater proportion of the pyridine. The dense material left at the bottom was dissolved in water and dialysed whilst maintaining a slightly alkaline pH. Concentration and then precipitation were performed, the latter by means of acetone to obtain a viscous liquid which, after dessication yielded 2.8 kg of the potassium salt of sulphated hydrodextran.

The reduction in number of the antilipid hydrodextr physiologic results of the effects of the antilipid of the liver and the reaction of the lipoids. weight, the liver fat of the contraphated by metabolis figures of lipoids of the p the expe be norm The per and did Conse salts of 45 firmed number which te ments of diets be 50 cause o

to stand, 15
The pH
precipita-
tion was
d hydro-
ents. By 20
o rabbits,
irs which
of Ediol
sity in 1
ately 0.5 25
°C.
s of the
an are:

The physico-chemical characteristics of the product are:

ash content	42.6%
hydrodextran	40.9%
sulphur	16.5%
refractive index (alpha)	+ 83°
quantity whose reducing power is equivalent to mg 50 of glucose	82.1 g.
intrinsic viscosity	0.04

To demonstrate the action of salts of sulphated hydrodextran on the metabolism of blood lipoids, experimental tests were carried out on laboratory animals (rabbits) which were fed on a high cholesterol diet and treated with a dosage of 5 mg/kg of body weight. The evaluation of the antilipaemic activity was made on the basis of determining the cholesterol, the total lipoids and the beta-alpha lipoprotein quotient in all animals prior to starting the tests, and at subsequent dates following the tests, between 30 and 94 days, and identical checks were performed on test animals which merely received the cholesterol diet.

The results of the tests demonstrated a reduction in the cholesterol values, total lipid number and beta/alpha quotient, testifying to the antilipaemic action of the salts of sulphated hydrodextran, the lipid values approximating physiological figures, in comparison with the results of the control groups demonstrating the effects of experimental hyperlipaemia.

At the end of the tests, all the animals were dispatched for comparative study of the weight of the liver, liver fat and liver fat cholesterol, and the results demonstrated the stimulating action of the product on the metabolism of the lipoids, lower values being found in the weight, triglycerides and cholesterol in the liver fat of the animals treated, compared to the controls. Accordingly, the salts of sulphated hydrodextran operate to stimulate the metabolism of the lipoids and to reduce the figures for cholesterol, the total number of lipoids and beta-alpha lipoprotein quotient.

The proteinogram was also established for the experimental animals, and was found to be normal throughout the experimental period. The period of coagulation was also verified and did not vary.

Consequently, the beneficial action of the salts of sulphated hydrodextran can be confirmed on the figures for cholesterol, total number of lipoids and beta/alpha quotient, which tends to balance the hyperlipaemic increments obtained experimentally with special diets based on fats and cholesterol liable to cause experimental atherosclerosis.

The salts of sulphated hydrodextran may, of course, be used in association with conventional pharmaceutical carriers or diluents and may be administered by any convenient route, although, as stated, they are particularly suitable for administration by the oral route.

WHAT WE CLAIM IS:—

1. An antilipaemic sulphated polysaccharide which comprises a salt of a sulphated hydrodextran, having an average content of from 1 to 3 SO₂ groups per monosaccharide group, and being substantially non-reducing as determined by the Somogyi method.

2. An antilipaemic sulphated polysaccharide according to claim 1, which has an intrinsic viscosity of from 0.02 to 0.07 at 25°C.

3. An antilipaemic sulphated polysaccharide according to claim 1 or claim 2, which comprises an alkali metal salt of said sulphated hydrodextran and which contains from 10 to 20% by weight of sulphur.

4. An antilipaemic sulphated polysaccharide according to claim 3, which is the sodium or potassium salt of said sulphated hydrodextran.

5. An antilipaemic sulphated polysaccharide according to claim 1 or claim 2, which is the salt of said sulphated hydrodextran and diethylamine, monoethylamine, pyridoxine or thiamine.

6. A method for the production of the antilipaemic sulphated polysaccharide of any one of the preceding claims, which comprises sulphating a hydrodextran having a reducing power, as determined by the Somogyi method, which is lower than 0.5%, expressed in terms of glucose, followed by salt formation.

7. A method according to claim 6, in which said hydrodextran has an intrinsic viscosity of from 0.02 to 0.07 at 25°C.

8. A method according to claim 6 or claim 7, in which the said hydrodextran is prepared by the hydrogenation of a dextran having a reducing power, as determined by the Somogyi method, between 5 and 10%, expressed in terms of glucose.

9. A method according to any one of claims 6, 7 and 8, in which said sulphation is effected to a degree of sulphation corresponding to an average of from 1 to 3 SO₂ groups per mono-

alcohol,
follow-
against
ractive
scosity

l. 3 kg
o 8 kg
irring,
below
d after
5 and
ixture
main-
to 10
utral-
lume)
lowed
opor-
il left
and
aline
ation
etone
sica-
lt of

saccharide group of the sulphated hydro-dextran.

10. A method according to claim 6, substantially as hereinbefore described.

5 11. An antilipaemic sulphated polysaccharide when prepared by the method of any one of claims 6 to 10.

10 12. An antilipaemic sulphated polysaccharide according to claim 1, substantially as hereinbefore described.

13. A composition comprising the antilipaemic sulphated polysaccharide of any of claims 1 to 5, 11 and 12, in association with a pharmaceutically acceptable carrier or diluent.

15

MARKS & CLERK,
Chartered Patent Agents,
Agents for the Applicants.

Printed for Her Majesty's Stationery Office by the Courier Press, Leamington Spa, 1969.
Published by the Patent Office, 25 Southampton Buildings, London, W.C.2, from which
copies may be obtained.